N@N

AFFX, AEZS, ADLS, ADLR, ACOR, ACAD, Biomed - Genetics Stocks 61.79% undervalued

^{Published on 2011-01-26 12:34:28 - WOPRAI}
 

January 26, 2011 / M2 PRESSWIRE / BUYINS.NET / http://www.squeezetrigger.com is monitoring the Biomed - Genetics sector and these stocks are the most undervalued as of today. AFFYMETRIX INC (NASDAQ:AFFX), AETERNA ZENTARIS INC (NASDAQ:AEZS), ADVANCED LIFE SCIENCES HOLD (OTCBB:ADLS), ADOLOR CORPORATION (NASDAQ:ADLR), ACORDA THERAPEUTICS INC (NASDAQ:ACOR), ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) are all expected to go Up as they are undervalued according to industry standard valuation metrics. The valuation model employs a three-factor approach to stock valuation using fundamental variables--the company's trailing 12-month Earnings-Per-Share (EPS), the analyst consensus estimate of the company's forecasted 12-month EPS, and the 30-year Treasury yield--to create a highly accurate reflection of a company's fair value.

The chart below displays the projected Fair Value and Valuation discount/premium of the most undervalued stocks in the highlighted industry group:

     Symbol     Company Name                        Last Close     Fair Value     Valuation                   Industry               
     AFFX       AFFYMETRIX INC                      4.99           13.06          61.79% undervalued          Biomed - Genetics      
     AEZS       AETERNA ZENTARIS INC                1.5899         2.77           42.64% undervalued          Biomed - Genetics      
     ADLS       ADVANCED LIFE SCIENCES HOLD         0.0255         0.2            87.50% undervalued          Biomed - Genetics      
     ADLR       ADOLOR CORPORATION                  1.36           5.44           75.00% undervalued          Biomed - Genetics      
     ACOR       ACORDA THERAPEUTICS INC             22.99          23.42          1.83% undervalued           Biomed - Genetics      
     ACAD       ACADIA PHARMACEUTICALS INC          1.71           6.84           75.00% undervalued          Biomed - Genetics      

Here are some of the variables that are utilized when calculating the Fair Market Valuation of a stock: Long-run EPS growth rate, Duration of Business-growth-cycle, Volatility of EPS growth rate, Systematic or beta risk of the firm, Correlation between the firm's EPS and the interest rate environment, EPS growth volatility, Dividend payout ratio, Buffer earnings, Interest rate related criteria: Interest rate (30 year yield) long-run level, Duration of interest rate cycle, Interest rate volatility. The Fair Market Valuation uses 12-month historic and forecasted EPS values and the current 30-year treasury yield as primary determinants. When calculating risk/return values such as the Sharpe ratio, the historic periods used are five years.

Some expected results of the Valuation Model are: the valuation of a stock increases in a declining interest rate environment. Increasing current and/or projected EPS will produce a higher Valuation. While long-term EPS growth would produce a corresponding long-term Valuation increase, concomitant long-term interest rate increases would offset EPS growth and depress the Valuation. The shorter a company's own business cycle, the higher its stock Valuation will be.

AFFYMETRIX INC (NASDAQ:AFFX) - Affymetrix, Inc. engages in the development, manufacture, sale, and servicing of consumables and systems for genetic analysis in the life sciences and clinical healthcare markets. The company offers integrated GeneChip microarray platform that includes disposable DNA probe arrays (chips) consisting of nucleic acid sequences, certain reagents for use with the probe arrays, a scanner and other instruments used to process the probe arrays, and software to analyze and manage genomic or genetic information obtained from the probe arrays. Its products are used in various applications, including genotyping and gene expression. The company sells its products directly to pharmaceutical, biotechnology, agrichemical, diagnostics, and consumer products companies; academic research centers; government research laboratories; private foundation laboratories; and clinical reference laboratories in North America and Europe, as well as through life science supply specialists acting as authorized distributors in Latin America, India, the Middle East, and the Asia Pacific regions, including the Peoples Republic of China. It has collaboration partnerships with Beckman Coulter, Inc.; CapitalBio Corporation; Life Technologies, Inc.; Genisphere LLC; and Qiagen GmbH. The company has operations in the United States, Europe, and Japan. Affymetrix, Inc. was founded in 1991 and is headquartered in Santa Clara, California.

AETERNA ZENTARIS INC (NASDAQ:AEZS) - terna Zentaris Inc. operates as a late-stage drug development company specialized in oncology and endocrinology. Its lead oncology compounds include perifosine, an orally active PI3K/Akt pathway inhibitor that is in Phase III registration trial for multiple myeloma; and AEZS-108, a doxorubicin-targeted conjugate in Phase II for the treatment of advanced ovarian and endometrial cancer. The companys lead endocrinology compound, AEZS-130, is an oral ghrelin antagonist in Phase III trial as a diagnostic test for Adult Growth Hormone Deficiency. Its pipeline also includes earlier-stage compounds, such as AEZS-112 that is in a Phase I trial in advanced solid tumors and lymphoma, as well as AEZS-120, an anti-cancer vaccine in pre-clinical development. The company was founded in 1991 and is headquartered in Quebec City, Canada.

ADVANCED LIFE SCIENCES HOLD (OTCBB:ADLS) - Advanced Life Sciences Holdings, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs in the areas of infectious disease, oncology, and respiratory disease. The companys lead product candidate includes Cethromycin, a once-a-day oral antibiotic for the treatment of respiratory tract infections, including community acquired pneumonia and biodefense pathogens, such as anthrax, plague, and tularemia. It is also developing ALS-357, a compound for the topical treatment of malignant melanoma; and ALS-886, a therapeutic for the treatment of inflammation-related tissue damage consisting of tissue damage associated with acute respiratory distress syndrome. The company has collaboration agreements with Abbott Laboratories and Pfizer to develop and commercialize cethromycin; University of Illinois to develop, make, use, and sell ALS-357 and related compounds; and Baxter International, Inc. Advanced Life Sciences Holdings, Inc. was founded in 1999 and is headquartered in Woodridge, Illinois.

ADOLOR CORPORATION (NASDAQ:ADLR) - Adolor Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of prescription pain management products. Its product includes ENTEREG (alvimopan), a small molecule peripherally-acting mu-opioid receptor antagonist designed to block the adverse side effects of opioid analgesics on the gastrointestinal (GI) tract, as well as to accelerate upper and lower GI recovery following partial bowel resection surgery with primary anastomosis. The company also has various product candidates in clinical development, which include two delta opioid receptor agonist compounds, ADL5859 and ADL5747, under Phase IIa clinical trial in collaboration with Pfizer Inc. for the treatment of pain; and two opioid receptor antagonists, ADL7445 and ADL5945, which are entering into Phase II clinical trial to treat opioid bowel dysfunction, as well as other product candidates in preclinical development for treating moderate-to-severe pain and other central nervous system conditions. Adolor Corporation was founded in 1993 and is headquartered in Exton, Pennsylvania.

ACORDA THERAPEUTICS INC (NASDAQ:ACOR) - Acorda Therapeutics, Inc., a biotechnology company, develops therapies for multiple sclerosis, spinal cord injury, and other nervous system disorders. Its marketed products include Ampyra (dalfampridine), a potassium channel blocker for improving walking in patients with multiple sclerosis; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The companys pipeline also includes various products in development for the treatment, regeneration, and repair of the spinal cord and brain. Its preclinical products comprise remyelination programs that include two distinct therapeutic approaches to stimulate repair of the damaged myelin sheath in multiple sclerosis, neuregulins/glial growth factor 2, and remyelinating antibodies; and chondroitinase program, which develops second generation approaches to overcoming the proteoglycan matrix. Acorda Therapeutics sells its products through specialty sales force, managed care team, and contract pharmaceutical telesales organizations. The company was founded in 1995 and is based in Hawthorne, New York.

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - ACADIA Pharmaceuticals, Inc., a biopharmaceutical company, focuses on drug discovery and clinical development of novel treatments for central nervous system disorders. The company is developing a portfolio of four product candidates, including pimavanserin, which is being developed for three separate neurological and psychiatric indications in collaboration with Biovail. These indications include Parkinsons disease psychosis that is in Phase III development; adjunctive therapy for schizophrenia, which is in Phase III planning; and Alzheimers disease psychosis, for which ACADIA is planning to initiate a Phase II feasibility study. The company also has other products under development, including a product candidate in Phase II development for chronic pain; and a product candidate in Phase I development for glaucoma, both in collaboration with Allergan, as well as a program in IND-track development in collaboration with Meiji Seika Kaisha. The products in ACADIAs pipeline emanate from discoveries made using its proprietary drug discovery platform. The company, formerly known as Receptor Technologies, Inc., was founded in 1993 and is headquartered in San Diego, California.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net